Ultragenyx Pharmaceutical Inc.

NASDAQ-GS: RARE

.USD

0.00 (0.00%)- today

Price at Apr 8, 4:00:01 PM EDT • Market Closed

Is it expensive?

Trailing P/E Ratio

Explainer

Trailing P/E shows what you are paying for each dollar of last year's earnings. It answers: "How expensive is this stock relative to its past year's profits?"

P/E Ratio: The expensive truth about cheap stocks

-3.97

Forward P/E Ratio

Explainer

Forward P/E shows what you are paying for each dollar of next year's projected earnings. It answers: "How expensive is this stock relative to its expected future profits?"

P/E Ratio: The expensive truth about cheap stocks

282.66

PEG Ratio

Explainer

PEG Ratio measures if a stock is expensive relative to its growth rate. It answers: "Am I paying a fair price for growth?"

PEG Ratio: The growth hunter's best friend

0.55

Enterprise Value to EBITDA

-5.49

Price-to-Sales (TTM)

Explainer

Price-to-Sales (TTM) shows what you pay for each dollar of the company's revenue. It answers: "How expensive is this stock relative to sales?"

3.34

Price-to-Book (MRQ)

-31.65

Book Value per Share (MRQ)

-0.83

Market Cap

Explainer

Market Cap calculates a company's market value. It answers: "How big is this company and what size risk am I taking?"

Market Cap: Sometimes size does matter

2.28B

Enterprise Value

2.74B

Is it profitable?

Net Profit Margin (TTM)

Explainer

Net Profit Margin (TTM) shows what percentage of revenue remains after all costs. It answers: "How much does the company keep as a final profit?"

Profit Margin: The key to measuring true business profitability

-85.44%

Gross Profit Margin

Explainer

Gross Profit Margin shows what percentage of revenue remains after direct costs. It answers: "How much does the company keep before operating costs?"

Profit Margin: The key to measuring true business profitability

85.84%

Diluted EPS (TTM)

Explainer

Diluted EPS (TTM) shows the profit per share over the last 12 months. It answers: "How profitable is each share I buy?"

Earnings per Share (EPS): The Key Metric That Beats Headline Profits

-5.83

Return on Equity (TTM)

-608.47%

Revenue (TTM)

673.00M

Is it growing?

Revenue Growth (MRQ)

25.90%

Earnings Growth (YOY)

25.72%

Is it risky?

Beta

0.25

Debt to Equity (MRQ)

-17.15

Current Ratio (MRQ)

2.48

Total Debt (MRQ)

1.25B

Who owns it?

Institutional Ownership

99.40%

Insider Ownership

3.20%

Short Interest

10.64%

Shares Outstanding

96.48M

Shares Float

92.93M

Does it pay?

Forward Dividend Yield

0.00%

Payout Ratio

0.00%

Ex. Dividend Date

Dividend Date

How much cash?

Total Cash (MRQ)

680.00M

Operating Cash Flow (TTM)

-466.00M

Levered Free Cash Flow (TTM)

-251.12M

Total Cash per Share (MRQ)

7.05

Indicators

Founder-operated companies generally perform better.

Founders

Dr. Emil D. Kakkis M.D., Ph.D.

CEO

Emil D. Kakkis

Biotechnology

Operating Cash Flow

-466.00M

÷0

Net Income

-575.00M

Backed by Cash

0.81

Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.

Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.

Indicators

Founder-operated companies generally perform better.

Founders

Dr. Emil D. Kakkis M.D., Ph.D.

CEO

Emil D. Kakkis

Biotechnology

Operating Cash Flow

-466.00M

÷0

Net Income

-575.00M

Backed by Cash

0.81

Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.

Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.

Is it expensive?

Trailing P/E Ratio

Explainer

Trailing P/E shows what you are paying for each dollar of last year's earnings. It answers: "How expensive is this stock relative to its past year's profits?"

P/E Ratio: The expensive truth about cheap stocks

-3.97

Forward P/E Ratio

Explainer

Forward P/E shows what you are paying for each dollar of next year's projected earnings. It answers: "How expensive is this stock relative to its expected future profits?"

P/E Ratio: The expensive truth about cheap stocks

282.66

PEG Ratio

Explainer

PEG Ratio measures if a stock is expensive relative to its growth rate. It answers: "Am I paying a fair price for growth?"

PEG Ratio: The growth hunter's best friend

0.55

Enterprise Value to EBITDA

-5.49

Price-to-Sales (TTM)

Explainer

Price-to-Sales (TTM) shows what you pay for each dollar of the company's revenue. It answers: "How expensive is this stock relative to sales?"

3.34

Price-to-Book (MRQ)

-31.65

Book Value per Share (MRQ)

-0.83

Market Cap

Explainer

Market Cap calculates a company's market value. It answers: "How big is this company and what size risk am I taking?"

Market Cap: Sometimes size does matter

2.28B

Enterprise Value

2.74B

Is it profitable?

Net Profit Margin (TTM)

Explainer

Net Profit Margin (TTM) shows what percentage of revenue remains after all costs. It answers: "How much does the company keep as a final profit?"

Profit Margin: The key to measuring true business profitability

-85.44%

Gross Profit Margin

Explainer

Gross Profit Margin shows what percentage of revenue remains after direct costs. It answers: "How much does the company keep before operating costs?"

Profit Margin: The key to measuring true business profitability

85.84%

Diluted EPS (TTM)

Explainer

Diluted EPS (TTM) shows the profit per share over the last 12 months. It answers: "How profitable is each share I buy?"

Earnings per Share (EPS): The Key Metric That Beats Headline Profits

-5.83

Return on Equity (TTM)

-608.47%

Revenue (TTM)

673.00M

Is it growing?

Revenue Growth (MRQ)

25.90%

Earnings Growth (YOY)

25.72%

Is it risky?

Beta

0.25

Debt to Equity (MRQ)

-17.15

Current Ratio (MRQ)

2.48

Total Debt (MRQ)

1.25B

Who owns it?

Institutional Ownership

99.40%

Insider Ownership

3.20%

Short Interest

10.64%

Shares Outstanding

96.48M

Shares Float

92.93M

Does it pay?

Forward Dividend Yield

0.00%

Payout Ratio

0.00%

Ex. Dividend Date

Dividend Date

How much cash?

Total Cash (MRQ)

680.00M

Operating Cash Flow (TTM)

-466.00M

Levered Free Cash Flow (TTM)

-251.12M

Total Cash per Share (MRQ)

7.05

Ultragenyx Pharmaceutical Inc.

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Indicators

Indicators

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Ultragenyx Pharmaceutical Inc.

Stock Details

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Indicators

Indicators

Stock Details

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers